Advances in Breast Cancer Screening, Diagnosis

Video

This video highlights recent studies advancing the field of breast cancer screening and diagnosis, including the potential need for increased surveillance in patients with false positives and patient access to mammography.

In this video, Sarah M. Friedewald, MD, of the Northwestern Medicine Feinberg School of Medicine in Chicago, highlights recent studies advancing the field of breast cancer screening and diagnosis, including patient access to mammography and the potential need for increased surveillance in patients with false positives, as they may be at increased risk for breast cancer.

Friedewald was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content